Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points

被引：7
|
作者：
Law, Ernest [1 ]
Gavanji, Roya [2 ]
Walsh, Sarah [3 ]
Haltner, Anja [3 ]
McTavish, Rebecca [2 ]
Cameron, Chris [3 ]
机构：
[1] Pfizer, New York, NY 10017 USA
[2] EVERSANA, Burlington, ON L7N 3H8, Canada
[3] EVERSANA, Sydney, NS B1P 1C6, Canada
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 11卷 / 02期
关键词：
abemaciclib; advanced breast cancer; health-related quality of life; HER2-negative; hormone receptor-positive; indirect treatment comparison; matching-adjusted indirect comparison; palbociclib; patient-reported outcomes; quality of life; QUALITY-OF-LIFE; MONARCH; 2; ABEMACICLIB; PLUS FULVESTRANT; COMBINATION; GUIDELINES; OUTCOMES; WOMEN; CARE;
D O I：
10.2217/cer-2021-0221
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To assess the relative impact of palbociclib plus fulvestrant (PAL + FUL) and abemaciclib plus fulvestrant (ABEM + FUL) on patient-reported outcomes in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Patients & methods: Anchored matching-adjusted indirect comparisons were conducted using individual patient data from PALOMA-3 (PAL + FUL) and summary-level data from MONARCH-2 (ABEM + FUL). Outcomes included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) and its breast cancer-specific module (QLQ-BR23). Results: Significantly different changes from baseline favoring PAL + FUL compared with ABEM + FUL were observed in global quality of life (6.95 [95% CI: 2.19-11.71]; p = 0.004) and several functional/symptom scales, including emotional functioning, nausea/vomiting, appetite loss, diarrhea and systemic therapy side effects. Conclusion: PAL + FUL was associated with more favorable patient-reported outcomes than ABEM + FUL in patients with HR+/HER2- advanced breast cancer.
引用
收藏
页码：109 / 120
页数：12
相关论文
共 50 条
  • [41] Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer
    Stellato, Daniel
    Thabane, Marroon
    Eichten, Caitlin
    Delea, Thomas E.
    CURRENT ONCOLOGY, 2021, 28 (01) : 491 - 508
  • [42] NETWORK META-ANALYSIS COMPARING PALBOCICLIB WITH CHEMOTHERAPIES FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED/METASTATIC BREAST CANCER
    Wilson, F. R.
    Varu, A.
    Mitra, D.
    Cameron, C.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A714 - A714
  • [43] Incidence of patient-reported fatigue developing in patients receiving palbociclib and endocrine therapy for advanced HR+HER2-breast cancer
    Rahman, Shadab A.
    Mayer, Erica L.
    Poort, Hanneke
    Schrag, Deborah
    Tung, Stephanie C.
    Zhou, Eric S.
    Wiley, Aleta
    Finkelstein, Lauren
    Elguenaoui, Elkhansaa
    Nolan, Moira
    Joffe, Hadine
    CANCER RESEARCH, 2022, 82 (04)
  • [44] Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer
    Bardia, A.
    Modi, S.
    Oliveira, M.
    Campone, M.
    Ma, B.
    Dirix, L.
    Weise, A.
    Nardi, L.
    Zhang, V.
    Bhansali, S. G.
    Hewes, B.
    Chavez-MacGregor, M.
    CANCER RESEARCH, 2016, 76
  • [45] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [46] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [47] Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer that had exhibited primary or secondary resistance to prior endocrine therapy
    Foster, C.
    Pivot, X.
    Llombart-Cussac, A.
    Neven, P.
    Lin, Y.
    Kaufman, P. A.
    Sledge, Jr G. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 290
  • [48] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis
    Goetz, Matthew P.
    Martin, Miguel
    Di Leo, Angelo
    Im, Seock-Ah
    Awada, Ahmad
    Forrester, Tammy
    Frenzel, Martin
    Cox, Joanne
    Barriga, Susana
    Toi, Masakazu
    Iwata, Hiroji
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S9 - S10
  • [50] Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
    Canino, Fabio
    Moscetti, Luca
    Borghi, Vanni
    Dominici, Massimo
    Piacentini, Federico
    BREAST CANCER MANAGEMENT, 2021, 10 (04)
12345